* If the product has intellectual property rights, a license granted is must or contact us.
Introduction of 218457-67-1 :
CB-103 is a first-in-class orally active notch signaling pathway inhibitor extracted from patent US9296682B2. CB-103 has anti-tumor activity. IC50 & Target: notch signaling pathwayIn Vitro: CB-103 acts as a Pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines. CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines. In Vivo: CB-103 inhibits NOTCH dependent cellular processes in mice. CB-103 blocks in vivo growth of PDX models of T-ALL. CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer. CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.